{
  "docId": "019de072-4b47-73db-b658-db74b88c61ed",
  "docSlug": "479ed371379fcba7e292c76acd5b0af7",
  "documentTitle": "BioNTech | Results Presentation Deck | 37 slides",
  "authorId": "biontech",
  "authorName": "BioNTech",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 22,
  "pageCount": 37,
  "prevPage": 21,
  "nextPage": 23,
  "slideType": "propose_solution",
  "function": "present_solution",
  "density": "overcrowded",
  "nDataPoints": 0,
  "notes": "Includes a citation of a Science paper and a process flow for the clinical trial design.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de072-4b47-73db-b658-db74b88c61ed/22",
  "deckHref": "/decks/019de072-4b47-73db-b658-db74b88c61ed",
  "deckJsonHref": "/decks/019de072-4b47-73db-b658-db74b88c61ed.json",
  "deckAnchorHref": "/decks/019de072-4b47-73db-b658-db74b88c61ed#slide-22",
  "components": [
    {
      "bbox": {
        "h": 0.3,
        "w": 0.65,
        "x": 0.3,
        "y": 0.6
      },
      "kind": "diagram",
      "text": "Clinical trial design flow: Patients -> Part 1/2 -> RP2D -> Part 3",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9cf3483f-ceee-4d12-b966-3c83d60499ff",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.25,
        "x": 0.04,
        "y": 0.55
      },
      "kind": "diagram",
      "text": "BNT211 CAR Structure diagram",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e5fe2e7a-1a63-41b9-bebb-7b7fb0ef19d0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.22,
        "x": 0.35,
        "y": 0.22
      },
      "kind": "image",
      "text": "CLDN6 expression images",
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "efd207f1-7ba1-432a-b1c0-6f3b0f2cd74d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.28,
        "x": 0.04,
        "y": 0.22
      },
      "kind": "list",
      "text": "2nd generation CAR-T: Directed against CLDN6, Cancer specific carcino-embryonic antigen, Expressed in multiple solid cancers with high medical need. CARVac: drives in vivo expansion, persistence and efficacy of CAR-T",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "55e6b281-b3ce-46ca-a625-80c9a9102d59",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.38,
        "x": 0.58,
        "y": 0.22
      },
      "kind": "quote",
      "text": "An RNA vaccine drives expansion and efficacy of claudin-CAR-T cells against solid tumors (Science)",
      "attrs": null,
      "subkind": "testimonial",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "36374bb4-2b5a-4bd3-81ce-980f842b1fea",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.7,
        "x": 0.04,
        "y": 0.93
      },
      "kind": "source-note",
      "text": "CLDN6, Claudin-6; CAR-T cells, chimeric antigen receptor engineered T cells; scFv, single chain variable fragment; RP2D, recommended Phase 2 dose; NOS, not otherwise specified; Reinhard K, et al. Science 2020; 367:446-453",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bf4c4e2b-0f54-4929-b3dc-0d39dfa1e9b8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.04,
        "y": 0.05
      },
      "kind": "title",
      "text": "BNT211: CAR-T Cell Program with Potential Targeting Multiple High-Need Solid Tumors",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a2eb3710-aa53-4a7a-ad27-70f99220eed7",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "process",
      "slug": null,
      "matchId": "025724ea-f77b-415e-8f85-bb93f452d1c8",
      "evidence": "Clinical trial design flow diagram",
      "confidence": 0.8
    }
  ],
  "arcBeats": [],
  "loops": [
    {
      "to": 24,
      "from": 22,
      "name": "Quick Win Big Bet",
      "slug": "47-quick-win-big-bet",
      "bestFor": "Transformation planning, 100-day plans, resource allocation",
      "matchId": "09024b0c-a4d8-4180-8644-ba27fdaa172f",
      "evidence": "The presentation highlights BNT211 as a potential solution for targeting multiple high-need solid tumors",
      "position": 1,
      "objective": "Presenting a potential solution with BNT211: CAR-T Cell Program",
      "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
      "confidence": 0.6,
      "description": "Separate initiatives into immediate wins and longer-term strategic bets"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}